LOLiliana Oliveira

Liliana Oliveira

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Liliana Oliveira has a total of 70 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Contactless body temperature assessment for signalling humane endpoints in a mouse model of sepsis

    by Catarina Miranda, Liliana Oliveira, Alexandre M Carmo, I Anna S Olsson, Nuno H Franco

    Minimising suffering is an ethical and legal requirement in animal research. This is particularly relevant for research on animal models of sepsis and septic shock, which show rapid progression towards severe stages and death. Specific and reliable criteria signalling non-recovery points can be used as humane endpoints, beyond which a study cannot be allowed to progress, thus preventing avoidable suffering. Body temperature is a key indicator for assessing animal health and welfare and has been suggested to have potential for monitoring the status of mouse models of sepsis. In this study, we monitored temperature variations using contactless methods – thermal imaging and subcutaneously implanted PIT tags – in a surgical model of sepsis by caecal ligation and puncture (CLP). We monitored body temperature variation following mid-grade CLP, high-grade CLP and sham surgery. All mice (Mus musculus) were monitored four times per day in the high-grade CLP model and three times per day in the mid-grade CLP model by both PIT tag readout and infrared thermography for ten days post-surgery, or until animals reached a predefined humane endpoint. Thermal data were compared with the clinical score and weight loss threshold used at our facility. Mean body surface temperature (MBST) assessed by thermal imaging and subcutaneous temperature (SCT) measured by PIT tags correlated, albeit not strongly. Moreover, while MBST does not appear to be a reliable predictor of non-recovery stages, SCT showed promise in this regard, even surpassing the widely used weight loss criterion, particularly for the high-grade CLP model of induced sepsis.


  • Open Access

    CD5L as a promising biological therapeutic for treating sepsis

    by Liliana Oliveira, M. Carolina Silva, Ana P. Gomes, Rita F. Santos, Marcos S. Cardoso, Ana Nóvoa, Hervé Luche, Bruno Cavadas, Irina Amorim, Fátima Gärtner, et al.

    Sepsis results from systemic, dysregulated inflammatory responses to infection, culminating in multiple organ failure. Here, we demonstrate the utility of CD5L for treating experimental sepsis caused by cecal ligation and puncture (CLP). We show that CD5L’s important features include its ability to enhance neutrophil recruitment and activation by increasing circulating levels of CXCL1, and to promote neutrophil phagocytosis. CD5L-deficient mice exhibit impaired neutrophil recruitment and compromised bacterial control, rendering them susceptible to attenuated CLP. CD5L-/- peritoneal cells from mice subjected to medium-grade CLP exhibit a heightened pro-inflammatory transcriptional profile, reflecting a loss of control of the immune response to the infection. Intravenous administration of recombinant CD5L (rCD5L) in immunocompetent C57BL/6 wild-type (WT) mice significantly ameliorates measures of disease in the setting of high-grade CLP-induced sepsis. Furthermore, rCD5L lowers endotoxin and damage-associated molecular pattern (DAMP) levels, and protects WT mice from LPS-induced endotoxic shock. These findings warrant the investigation of rCD5L as a possible treatment for sepsis in humans.


  • Open Access

    The dual character of the inhibitory functions of CD6

    by Rita F. Santos, Annika De Sousa Linhares, Marcos S. Cardoso, Ana Nóvoa, Hervé Luche, Fátima Gärtner, Bernard Malissen, Peter Steinberger, Simon. J. Davis, Moisés Mallo, et al.

    T-cell membrane scaffold proteins play important roles in T cell biology, functioning as multi-functional signaling hubs. CD6 assembles a large intracellular signalosome but, unlike typical membrane-attached scaffolds like LAT or PAG, it has a sizeable ectodomain that binds a well-characterized ligand, CD166. It is unclear whether CD6 has net inhibitory or costimulatory functions or how its ectodomain influences these activities. To explore these questions, we dissected the signaling functions of the extracellular and cytoplasmic regions of CD6. We found that CD6 was delivered to the immunological synapse and suppressed T cell responsiveness in vitro wholly dependently of its cytoplasmic domain, indicating that CD6 very potently imposes tonic inhibition, acting as a structural and signaling inhibitory hub. However, the cell-intrinsic suppression of autoimmunity by CD6 in vivo was also impacted by extracellular interactions, demonstrated by the increased susceptibility of mice to experimental autoimmune encephalomyelitis after removal of the ligand binding region of the ectodomain of CD6. Our work identifies CD6 as a new class of ‘on/off switching’ scaffold-receptor that constrains immune responsiveness at two speeds. First, it sets signaling thresholds via tonic inhibition, functioning as a cytoplasmic membrane-bound scaffold and, second, by cycling between signaling-enabling and signalinginhibiting ectodomain isoforms it functions as an immune checkpoint.


  • ThermoLabAnimal – A high-throughput analysis software for non-invasive thermal assessment of laboratory mice

    by Nuno Henrique Franco, Ana Gerós, Liliana Oliveira, I. Anna S. Olsson, Paulo Aguiar


  • Open Access

    Domain‐specific CD6 monoclonal antibodies identify CD6 isoforms generated by alternative‐splicing

    by Rita F. Santos, Liliana Oliveira, Marion H. Brown, Alexandre M. Carmo

    Summary: The characterization of the architecture, structure and extracellular interactions of the CD6 glycoprotein, a transmembrane receptor expressed in medullary thymocytes and all mature T‐cell populations, has been enhanced by the existence of monoclonal antibodies (mAbs) that specifically recognize the various scavenger receptor cysteine‐rich (SRCR) domains of the ectodomain. Using engineered isoforms of CD6 including or excluding each of the three SRCR domains, either expressed at the membranes of cells or in soluble forms, we provide conclusive and definitive evidence that domain 2 of CD6, previously not identifiable, can be recognized by the CD6 mAbs OX125 and OX126, and that OX124 targets domain 3 and can block the interaction at the cell surface of CD6 with its major ligand CD166. Alternative splicing‐dependent CD6 isoforms can now be confidently identified. We confirm that following T‐cell activation there is a partial replacement of full‐length CD6 by the CD6Δd3 isoform, which lacks the CD166‐binding domain, and we find no evidence for the expression of other CD6 isoforms at the mRNA or protein levels.


  • CD6

    by Liliana Oliveira, Rita F. Santos, Alexandre M. Carmo

  • Open Access

    Response: Commentary: The Scavenger Receptor SSc5D Physically Interacts with Bacteria through the SRCR-Containing N-Terminal Domain

    by Liliana Oliveira, Alexandre M. Carmo

    Response: Commentary: The Scavenger Receptor SSc5D Physically Interacts with Bacteria through the SRCR-Containing N-Terminal Domain


  • Open Access

    The Scavenger Receptor SSc5D Physically Interacts with Bacteria through the SRCR-Containing N-Terminal Domain

    by Catarina Bessa Pereira, Markéta Bocková, Rita F. Santos, Ana Mafalda Santos, Mafalda Martins de Araújo, Liliana Oliveira, Jiří Homola, Alexandre M. Carmo

    The scavenger receptor cysteine-rich (SRCR) family comprises a group of membrane-attached or secreted proteins that contain one or more modules/domains structurally similar to the membrane distal domain of type I macrophage scavenger receptor. Although no all-inclusive biological function has been ascribed to the SRCR family, some of these receptors have been shown to recognize pathogen-associated molecular patterns (PAMP) of bacteria, fungi or other microbes. SSc5D is a recently described soluble SRCR receptor produced by monocytes/macrophages and T lymphocytes, consisting of an N-terminal portion which contains five SRCR modules, and a large C-terminal mucin-like domain. Towards establishing a global common role for SRCR domains, we interrogated whether the set of five SRCR domains of SSc5D displayed pattern recognition receptor (PRR) properties. For that purpose, we have expressed in a mammalian expression system the N-terminal SRCR-containing moiety of SSC5D (N-SSc5D), thus excluding the mucin-like domain likely by nature to bind microorganisms, and tested the capacity of the SRCR functional groups to physically interact with bacteria. Using conventional protein-bacteria binding assays, we showed that N-SSc5D had a superior capacity to bind to E. coli strains RS218 and IHE3034 compared with that of the extracellular domains of the SRCR proteins CD5 and CD6 (sCD5 and sCD6, respectively), and similar E. coli-binding properties as Spα, a proven PRR of the SRCR family. We have further designed a more sensitive, real-time and label-free surface plasmon resonance (SPR)-based assay, and examined the capacity of N-SSc5D, Spα, sCD5 and sCD6 to bind to different bacteria. We demonstrated that the N-SSc5D compares with Spα in the capacity to bind to E. coli and L. monocytogenes, and further that it can distinguish between pathogenic E. coli RS218 and IHE3034 strains and the non-pathogenic laboratory E. coli strain BL21(DE3). Our work thus advocates the utility of SPR-based assays as sensitive tools for the rapid screening of interactions between immune-related receptors and PAMP-bearing microbes. The analysis of our results suggest that SRCR domains of different members of the family have a differential capacity to interact with bacteria, and further that the same receptor can discriminate between different bacteria strains and species.


  • Tuning T Cell Activation: The Function of CD6 At the Immunological Synapse and in T Cell Responses

    by Rita F. Santos, Liliana Oliveira, Alexandre M. Carmo

    CD6 immunotherapy to treat psoriasis and rheumatoid arthritis has reached the clinical trial stage with apparent success, and targeting CD6 with mAbs is being used in several animal models of autoimmunity and neuroinflammation with promising indications. However, the mode of action of the therapeutic CD6 mAbs is far from being understood, reflecting the uncertainties and controversy surrounding the mechanistic and biological functions of CD6. Initially regarded as a co-stimulatory receptor of T lymphocytes, recent studies suggest that CD6 can instead modulate early as well as late T cell responses. Also, opposing the contribution of CD6 adhesiveness in the establishment and stabilization of immunological synapses, the actual triggering of CD6 might induce anti-proliferative signals to the T lymphocyte. CD6 has an unusually long cytoplasmic tail and its gene undergoes peculiar patterns of activation-dependent alternative splicing that can on one hand determine whether or not the CD6 protein binds to its ligand, and on the other include or exclude intracellular sequences that may transduce positive or negative signaling. In this review we discuss the multiple aspects that determine the nature of the signals transmitted via CD6 and the context that may define a dual role for this important T cell surface molecule.


  • Open Access

    CD5 expression is regulated during human T‐cell activation by alternative polyadenylation, PTBP1, and miR‐204

    by Rita G. Domingues, Inês Lago‐Baldaia, Isabel Pereira‐Castro, Joseph M. Fachini, Liliana Oliveira, Danica Drpic, Nair Lopes, Telmo Henriques, Joel R. Neilson, Alexandre M. Carmo, et al.

    T lymphocytes stimulated through their antigen receptor (TCR) preferentially express mRNA isoforms with shorter 3´ untranslated regions (3´‐UTRs) derived from alternative pre‐mRNA cleavage and polyadenylation (APA). However, the physiological relevance of APA programs remains poorly understood. CD5 is a T‐cell surface glycoprotein that negatively regulates TCR signaling from the onset of T‐cell activation. CD5 plays a pivotal role in mediating outcomes of cell survival or apoptosis, and may prevent both autoimmunity and cancer. In human primary T lymphocytes and Jurkat cells we found three distinct mRNA isoforms encoding CD5, each derived from distinct poly(A) signals (PASs). Upon T‐cell activation, there is an overall increase in CD5 mRNAs with a specific increase in the relative expression of the shorter isoforms. 3´‐UTRs derived from these shorter isoforms confer higher reporter expression in activated T cells relative to the longer isoform. We further show that polypyrimidine tract binding protein (PTB/PTBP1) directly binds to the proximal PAS and PTB siRNA depletion causes a decrease in mRNA derived from this PAS, suggesting an effect on stability or poly(A) site selection to circumvent targeting of the longer CD5 mRNA isoform by miR‐204. These mechanisms fine‐tune CD5 expression levels and thus ultimately T‐cell responses.